RxDoctor Payments Data

Miyako Tamada

Family · Philadelphia, PANPI 1861154403

Payments from drug & device makers

$635in general payments, 2019–2025

Across 35 payments — averaging $18.15 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$186
  • Lilly USA, LLC$62
  • Novo Nordisk$56
  • AbbVie$50
  • Novartis$47
  • Boehringer Ingelheim$46
  • plus $189 from 7 others

What the payments were for

  • Food & beverage$635100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$635 in reported general payments places this provider in the 60th percentile of 4,717 family providers in Pennsylvania.

See all family providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$4,652
Medicare patients
16
Services billed
57

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
FarxigaDapagliflozin Propanediol91$76,995
EliquisApixaban37$30,647
JardianceEmpagliflozin23$24,372
TrulicityDulaglutide21$24,087
OzempicSemaglutide20$18,239
Trelegy ElliptaFluticasone/Umeclidin/Vilanter17$10,369
XareltoRivaroxaban12$9,688
LinzessLinaclotide17$9,143
Albuterol Sulfate HfaAlbuterol Sulfate99$4,468
Lantus SolostarInsulin Glargine,hum.Rec.Anlog25$2,255
Atorvastatin Calcium210$1,660
Cyclobenzaprine Hcl47$1,124
Gabapentin77$1,059
Colchicine11$1,019
Diclofenac Sodium29$1,006

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaFarxiga$186$76,99591 claims
Boehringer IngelheimJardiance$46$24,37223 claims
Lilly USA, LLCTrulicity$62$24,08721 claims
Novo NordiskOzempic$56$18,23920 claims
GSKTrelegy Ellipta$37$10,36917 claims
Johnson & JohnsonXarelto$45$9,68812 claims
AbbVieLinzess$50$9,14317 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 4,717 family providers in Pennsylvania.

Other family in Philadelphia

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →